ANAPTYSBIO, INC cotiza a 45.59 USD y tiene una capitalización bursátil de $1.4B. En los últimos 12 meses ha facturado $232M con un margen de flujo de caja libre del 8.4%. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
AnaptysBio, Inc. discovers and out-licenses therapeutic bodies in the United States. The company manages financial collaborations for Jemperli, a PD-1 antagonist for various solid tumor indications; and Quimilza, an IL-36R antagonist mAb, which has completed two registration-enabling global Phase 3 trials, and GEMINI-1…
| Periodo | 2026-11 | 2026-09 | 2026-03 | 2025-11 |
|---|---|---|---|---|
| Real | — | $4.93 | $1.58 | $0.52 |
| Estimado | $0.80 | $0.14 | $0.93 | $-1.25 |
| Sorpresa | — | +3421.4% | +69.9% | +141.6% |
| Métrica | ANAB | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | 20.4% | -38.6% | +59.0% |
| Net Margin | -5.6% | -33.6% | +27.9% |
| FCF Margin | 8.4% | -13.9% | +22.2% |
| ROE | -35.6% | -40.4% | +4.8% |
| ROA | -3.6% | -32.0% | +28.4% |
| Current Ratio | 9.07 | 2.84 | +6.23 |
| Debt / Equity | — | 0.28 | — |